公开(公告)号：KR3005576170000S

公开(公告)日：2010-04-12

申请号：KR3020090005190

申请日：2009-02-10

Applicant: (주)아모레퍼시픽

Designer： 기한뫼 ,  최양규

公开(公告)号：KR1020090132173A

公开(公告)日：2009-12-30

申请号：KR1020080058303

申请日：2008-06-20

Applicant: (주)아모레퍼시픽 ,  주식회사 에스트라

Inventor： 기한뫼 ,  최양규 ,  아영창 ,  배준호

IPC: A61K9/70 ,  A61K31/122

Abstract: PURPOSE: A transdermal absorption composition containing loxoprofen or its salt is provided to suppress generation of crystallization and ensure adhesion which is applicable to joint of human body. CONSTITUTION: A transdermal absorption composition contains 0.5-50 weight% of loxoprofen or its salt, 7-15 weight% of glycerol monolaurate as absorber, 20-92 weight% of adhesion polymer and 0.1-20 weight% of sorbitan ester as a stabilizing agent. The sorbitan ester is sorbitan sesquioleate or sorbitan sesquistearate. The composition further contains acetic acid, lactic acid or myristic acid. The salt of loxoprofen is loxoprofen sodium.

Abstract translation: 目的：提供含有洛索洛芬或其盐的透皮吸收组合物，以抑制结晶的产生并确保适用于人体关节的粘合。 构成：透皮吸收组合物含有0.5-50重量％的洛索洛芬或其盐，7-15重量％的甘油单月桂酸酯作为吸收剂，20-92重量％的粘合聚合物和0.1-20重量％的脱水山梨醇酯作为稳定剂 。 脱水山梨糖醇酯是脱水山梨糖醇倍半油酸酯或脱水山梨糖醇倍半硬脂酸酯。 组合物还含有乙酸，乳酸或肉豆蔻酸。 洛索洛芬的盐是洛索洛芬钠。

公开(公告)号：KR1020080006961A

公开(公告)日：2008-01-17

申请号：KR1020060066357

申请日：2006-07-14

Applicant: (주)아모레퍼시픽 ,  주식회사 에스트라

Inventor： 기한뫼 ,  최양규 ,  아영창 ,  김정주

IPC: A61K9/70

CPC classification number: A61K9/7038 ,  A61K31/192 ,  A61K31/196

Abstract: A transdermal preparation is provided to promote the drug absorption by the skin hydration through a hydrophobic adhesive layer, show continuous and high effect of a drug by maintaining the thermodynamic activity of the hydrophobic drug in an adhesive caused by moisture discharged from skin and be able to reduce the cost and the time due to a very simple preparing process. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug containing adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an absorption promoting agent, where a hydrophobic adhesive of the hydrophobic adhesive layer is selected from the group consisting of polyisobutylene adhesive, styrene-isoprene-styrene adhesive, and styrene-butadiene-styrene adhesive, the drug containing adhesive layer is an acrylate polymer made from acrylate, hydroxypropyl acrylate, acrylamide, acrylamide vinyl acetate, vinyl derivative, methacrylate, hydroxypropyl methacrylate and methacrylamide. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.

Abstract translation: 提供透皮制剂以通过疏水粘合剂层通过皮肤水合促进药物吸收，通过将疏水药物的热力学活性保持在由皮肤排出的水分引起的粘合剂中，显示出药物的连续和高效果，并且能够 由于非常简单的准备过程，降低了成本和时间。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 和层叠在疏水性粘合剂层下面的药物含有粘合剂层（3）的药物包含药物，并将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药， 吸水促进剂，其中疏水性粘合剂层的疏水性粘合剂选自聚异丁烯粘合剂，苯乙烯 - 异戊二烯 - 苯乙烯粘合剂和苯乙烯 - 丁二烯 - 苯乙烯粘合剂，所述药物粘合剂层是由 丙烯酸酯，丙烯酸羟丙酯，丙烯酰胺，丙烯酰胺乙酸乙烯酯，乙烯基衍生物，甲基丙烯酸酯，甲基丙烯酸羟丙酯和甲基丙烯酰胺。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。

公开(公告)号：KR1020080006960A

公开(公告)日：2008-01-17

申请号：KR1020060066353

申请日：2006-07-14

Applicant: (주)아모레퍼시픽 ,  주식회사 에스트라

Inventor： 최양규 ,  기한뫼 ,  아영창 ,  김정주

IPC: A61K9/70

CPC classification number: A61K9/7061 ,  A61K47/32

Abstract: A transdermal preparation is provided to continuously allow a highly concentrated hydrophobic drug to be absorbed into skin until a patch is detached from the skin with minimized skin side effects and provide the enough adhesive capability during the time of exhibiting the medical efficacy by being attached to the skin. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an acryl adhesive agent and the acryl adhesive agent includes a hydrophilic monomer promoting the skin absorption from the skin and is selected from the group consisting of acrylic acid, methyl methacrylate, ethyl acrylate, hydroxyethyl acrylate, butyl acrylate, octyl acrylate, 2-ethylhexyl acrylate, and hexyl acrylate. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.

Abstract translation: 提供透皮制剂以连续地允许高度浓缩的疏水性药物被吸收到皮肤中，直到贴片从皮肤上分离出来，使皮肤的副作用最小化，并且在展示医疗功效的时间期间提供足够的粘合能力， 皮肤。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 以及层叠在疏水性粘合剂层下方的药物粘合剂层（3），包括药物，并且将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药和 丙烯酸粘合剂和丙烯酸粘合剂包括促进皮肤吸收皮肤的亲水单体，并且选自丙烯酸，甲基丙烯酸甲酯，丙烯酸乙酯，丙烯酸羟乙酯，丙烯酸丁酯，丙烯酸辛酯，丙烯酸2-乙基己酯， 和丙烯酸己酯。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。

公开(公告)号：KR1020070108688A

公开(公告)日：2007-11-13

申请号：KR1020060041041

申请日：2006-05-08

Applicant: (주)아모레퍼시픽

Inventor： 아영창 ,  우병영 ,  최양규 ,  기한뫼

IPC: A61K9/70 ,  A61P29/00

CPC classification number: A61K9/7053 ,  A61K9/7061 ,  A61K9/7084

Abstract: A composition for transdermal absorption is provided to increase solubility of non-steroidal anti-inflammatory drug as an effective ingredient by using a small amount of solubilizer, thereby containing high concentration of effective ingredient without skin irritation. A formulation comprising a polymeric matrix is also provided to maximize skin absorption of the effective ingredient. A composition for transdermal absorption comprises 0.1-50 wt.% of a non-steroidal anti-inflammatory drug, 0.01-10 wt.% of alkali metal-containing alcohol derivatives represented by the formula(1): M-O-R in which M is a Group I metal, O is oxygen and R is C1-5 alkyl as a solubilizer, 40-98 wt.% of a polymer adhesive and a volatile solvent. A formulation for transdermal absorption comprises a release paper, a polymeric matrix(2) prepared by coating the release paper(3) with the composition for transdermal absorption, and a support(1), sequentially, and has the thickness of 10-120 mum.

Abstract translation: 提供透皮吸收用组合物以通过使用少量增溶剂来增加非甾体抗炎药物作为有效成分的溶解度，由此含有高浓度的有效成分而不引起皮肤刺激。 还提供了包含聚合物基质的制剂以使有效成分的皮肤吸收最大化。 用于经皮吸收的组合物包含0.1-50重量％的非甾体抗炎药，0.01-10重量％的由式（1）表示的含碱金属的醇衍生物：MOR，其中M是一个 I金属，O是氧，R是作为增溶剂的C 1-5烷基，40-98重量％的聚合物粘合剂和挥发性溶剂。 用于透皮吸收的制剂包括脱模纸，通过用离子纸（3）涂覆用于经皮吸收的组合物和支撑体（1）制备的聚合物基质（2），并且具有10-120μm的厚度 。